INDIA – LordsMed, a division of Lords Mark Industries Pvt Ltd, has signed a distribution deal with Hindustan Antibiotics Limited (HAL), India’s first public sector undertaking in the Drugs & Pharmaceutical Sector.

LordsMed and HAL have entered into an exclusive distribution agreement to make affordable rapid antigen kits available to healthcare professionals across India.

The partnership will build on LordsMed’s ongoing endeavours to broaden its distribution network, which is part of its goal of facilitating early-stage healthcare intervention and generating Rs 75 crore in revenue in six months.

It is part of the innovator’s mission to build a robust early-stage healthcare intervention framework and boost the responsiveness of the healthcare ecosystem.

In addition, the covid rapid antigen test kit will emerge as a critical tool to curb the pandemic impact in India in concerted efforts to boost pandemic preparedness and response.

Sachidanand Upadhyay, Chief Executive Officer (CEO) of Lord’s Mark Industries, said: “The distribution partnership with HAL will help us reach out to all parts of the country cities including metros, Tier -1, 2 and 3 cities and rural areas with our affordable and advanced rapid antigen test kits.”

He pointed out that they are working towards capturing the global and domestic demand spectrum while adhering to stringent quality and regulatory compliance.

LordsMed manufactures an extensive range of rapid test kits for detecting malaria, cardiovascular disease, hepatitis C virus (HCV), HIV, syphilis, hepatitis B surface antigen (HBsAg), dengue, typhoid, COVID, chikungunya, ovulation, and pregnancy.

With a robust Research and development (R&D) team comprised of experienced microbiologists and doctors, it has emerged as the only in vitro diagnostics (IVDs) kit manufacturing company in India.

The CE-certified company announced that it would manufacture rapid antigen test kits and distribute its testing devices to government healthcare centers across India valued at approximately 10 percent less than the average market rates.

The company boasts of advanced manufacturing capabilities to produce rapid test kits which come with a 98 percent accuracy,” LordsMed said in an official note.

Under the distribution pact with HAL, LordsMed will manufacture the affordable rapid antigen test kits at its ICMR-approved GMP and ISO-certified facility at Vasai, near Mumbai, Maharashtra.

LordsMed announced that it has plans to roll out saliva-based diagnostic solutions for a range of diseases, noting that the company has successfully carried out trials of its saliva-based diagnostics kits for diabetes and liver diseases.

We foresee the emergence of saliva as a non-invasive diagnostic method,” Sachidanand Upadhyay, Lord’s Mark Industries CEO, added.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.